Recent guidelines have broadened the indication for statin treatment and intensive cholesterol lowering in subjects without coronary artery disease affected by comorbidities, including diabetes mellitus, peripheral arterial diseases, or renal dysfunction, that portend very high CV risk, wrote the authors, the majority of whom conducted the research at Federico II University in Naples, Italy.